
United States CPT Code Confirmation for LiverSmart®

Highlights

- Independent CPT code certifier confirms US CPT Code eligibility for LiverSmart®
- Code eligibility is a major milestone in the pathway to reimbursement in the USA
- CPT Codes are national procedural codes published by the American Medical Association
- CPT Codes describe medical services for reimbursement by government + private payers
- Government insurers, including Medicare and Medicaid, provide coverage for 115m people
- Over 300 million people in the USA have government or private health insurance¹

CPT Codes Certified as Applicable to LiverSmart®

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or the “Company”) has received confirmation from an independent US CPT Code Certifier that its LiverSmart® medical device is eligible for up to two new US (Category III) Current Procedural Terminology (“CPT”) codes. The Company engaged the services of KarenZupko & Associates, Inc., based in Chicago, Illinois, USA, (“KZA”) to perform the review, which was conducted by Mr. Matthew Twetten MA MHCDS.

KZA reviewed the Company’s LiverSmart® User Guide, the 2022 CPT Professional Coding Guide published and maintained by the American Medical Association (“AMA”), and various materials relating to new CPT codes 0648T and 0649T which became effective on 1 January 2022. KZA recommends that CPT code 0648T applies when LiverSmart® is performed without other documented diagnostic liver imaging, and CPT code 0649T applies when additional diagnostic liver imaging is performed in the same scanning session.

CPT Code Eligibility – Key Milestone Towards US Reimbursement for LiverSmart®

CPT codes are a set of codes, descriptions and guidelines maintained by the AMA and recognised by US government agencies and private insurers. They describe medical procedures and services performed by physicians and other healthcare providers for reimbursement by government payers such as Medicare and Medicaid, and private payers including private health insurers. The codes are used by physicians and healthcare providers for reporting and tracking medical services performed by healthcare providers.

CPT codes generally start as Category III codes and, when there is sufficient reporting of the codes and adequate literature supporting efficacy, they can be upgraded to Category I which are widely accepted by third party payors. CPT code eligibility for medical devices, procedures, and services, are the first formal step into the US national reimbursement coding framework. The new Cat III codes can immediately be used by hospitals and MRI imaging centres in the United States when using LiverSmart®.

Resonance Health Managing Director, Mr. Michell Wells, commented:

“The confirmation of applicability of two new CPT codes represents a major milestone in the pathway to more widespread reimbursement of LiverSmart® in the United States. Our US sales team can now advise our customers of the applicability of these new codes, which adds to the credibility of our new recently FDA cleared LiverSmart® medical device. CPT coding can enhance the take-up of new products and, if the codes convert to Category I, they should greatly enhance patient accessibility to LiverSmart® as an important diagnostic service by removing affordability barriers. Ultimately, our goal is to achieve third party reimbursement of our services so the barrier of affordability for the patient is removed. CPT coding is a critical milestone toward that objective.”

About KarenZupko & Associates, Inc.

KZA is a consulting firm that has, for over 35 years, assisted physicians and healthcare organizations to increase revenue, optimize efficiency, reduce risk, and improve patient experience. Led by international thought leader, Karen Zupko, KZA has been advising and educating physicians and healthcare managers for decades about the challenges and trends impacting the practice of medicine. The KZA team includes physicians, nurses, and former administrators, who have managed practices and academic departments and delivered patient care.

Reviewer’s Qualifications

The review was led by KZA’s Mr. Matthew Twetten, MA MHCDS. Mr. Twetten’s experience includes 18 years in physician specialty societies and as staff liaison to the American Medical Association CPT Editorial Panel. He has authored CPT coding articles for publications including ‘AAOS Now’ and ‘SpineLine’ and has authored CPT applications. He has also presented directly to the CPT Editorial Panel. Mr. Twetten has a Masters in Healthcare Delivery Science, from Dartmouth University, and a Masters of Arts, from the State University of New York – Binghamton.

About LiverSmart®

LiverSmart® provides accurate measurement of liver-iron-concentration and liver-fat through non-invasive MRI technology. It combines two existing Resonance Health AI products, FerriSmart® and HepaFat-AI®, into a single multi-parametric MRI session, avoiding the need for multiple MRI appointments, and delivering a more complete and comprehensive assessment of a person’s liver. LiverSmart® obtained US Food & Drug Administration (“FDA”) regulatory clearance on 30 December 2021.



This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd.

For further information please contact:

Mitchell Wells

Managing Director, Resonance Health Ltd

E: mitchellw@resonancehealth.com

P: +61 (0)8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company, specialising in the development and delivery of noninvasive medical imaging software and services.

The Company's products are used globally by clinicians in the diagnosis and management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for consistently providing high quality quantitative measurements essential in the diagnosis and management of diseases.

Resonance Health's dedication to scientific rigour and quality management has enabled it to achieve regulatory clearances for a range of Software as a Medical Device (**SaMD**) products in the USA, Europe, and Australia and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Some of the SaMD products incorporate the use of Artificial Intelligence (**AI**):

- **FerriScan**[®] - a core-lab product that provides accurate measurement of liver iron concentration through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart**[®] - an AI-driven non-invasive MRI-based device for the automated real-time measurement of liver iron concentration in patients.
- **HepaFat-AI**[®] - an AI-driven non-invasive MRI-based device for the automated real-time multi-metric measurement of liver fat in patients, for use in the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart**[®] - an AI-driven non-invasive MRI-based multi-parametric device that combines FerriSmart[®] and HepaFat-AI[®] into a consolidated report that provides accurate measurement of liver iron concentration and liver fat.
- **CardiacT2*** – the most widely accepted MRI-based method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan[®] and CardiacT2*. CardiacT2* has regulatory clearance from the TGA and CE Mark.

The Company has an active development pipeline of additional medical imaging analysis products and services, including, **LungSmart**[®] and **Alert-PE**[™], AI tools for the automated review of chest CT scans of patients with cystic fibrosis and suspected pulmonary embolism, respectively.

Stakeholders including clinicians and patients are encouraged to follow Resonance Health on FaceBook, LinkedIn and Twitter.



¹ Unites States Census Bureau, Health Insurance Coverage in the United States: 2020, Katherine Keisier-Starkey and LisaN. Bunch, Issued Sep 2021: <https://www.census.gov/content/dam/Census/library/publications/2021/demo/p60-274.pdf>